Boehringer Ingelheim half-year results 2023 Boehringer Ingelheim half-year results 2023 First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Brand of the Year Frontline pet parasiticides Brand of the Year Frontline pet parasiticides FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
Ranking in the top 25% in EcoVadis Sustainability Assessment Ranking in the top 25% in EcoVadis Sustainability Assessment Boehringer Ingelheim has received a silver medal from EcoVadis in the 2023 sustainability assessment, including above industry average scores.
SENVELGO Best New Product Companion Animals award SENVELGO Best New Product Companion Animals award SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
Accelerating new cancer medicines in partnership with CBmed Accelerating new cancer medicines in partnership with CBmed Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Our mission in cardiovascular, renal, and metabolic care Our mission in cardiovascular, renal, and metabolic care Interconnected cardiovascular, renal, and metabolic diseases affect over 1 billion lives globally
Lifelong learning at our Virtual Campus Lifelong learning at our Virtual Campus The Virtual Campus of our Boehringer Ingelheim University supports our employees in their personalized lifelong learning.
Earthquakes Türkiye & Syria Earthquakes Türkiye & Syria Support for those impacted by Türkiye & Syria earthquakes
Our Partners_ViraTherapeutics Our Partners_ViraTherapeutics Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Circular economy Circular economy Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.
Gerhard Kraus, Global Head of IT Infrastructure Gerhard Kraus, Global Head of IT Infrastructure Gerhard Kraus, Global Head of IT Infrastructure "Improving the health of humans and animals is our vision. What we do can make a huge impact"
Innovation in medicinal chemistry Innovation in medicinal chemistry Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Spesolimab Phase II data Spesolimab Phase II data New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
The Boehringer Ingelheim Veterinary Scholars Program The Boehringer Ingelheim Veterinary Scholars Program The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Option to Acquire Trutino Biosciences Option to Acquire Trutino Biosciences Option to Acquire Trutino Biosciences
Working with purpose Working with purpose Colleagues tell their personal stories and what motivates them to contribute towards a better future for generations to come.
Bernard Mental Health Impact Bernard Mental Health Impact Harold and Friends learn about how living with multiple health conditions can impact mental health
Dogs at work in Milan offices Dogs at work in Milan offices Dogs at work is a pilot project that allows pet-lover to bring their dogs to the office and enjoy the benefits they bring to their daily work life.
It’s Your Heart. Protect It. The Podcast. It’s Your Heart. Protect It. The Podcast. In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
World-Psoriasis-Day-IFPA-Interview World-Psoriasis-Day-IFPA-Interview Interview with the International Federation of Psoriasis Associations (IFPA)
Lothar Halmer Lothar Halmer Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.